A clinical case report describes a remarkable response in a patient with GBM [33]; this is the first reported GBM patient treated successfully with a CXCR4 inhibitor (Plerixafor/AMD3100, as part of an adjuvant therapeutic strategy); the patient showed no evidence of recurrent disease during 2 years of continuous treatment. This evidence concerns the gene CXCR4 and glioblastoma.